Antipsychotic polypharmacy and psychopharmacological prescription patterns in long stay psychiatry hospitalization: 1995-2009 comparison
DOI:
https://doi.org/10.20453/rnp.v85i1.4150Keywords:
drug utilization, polypharmacy, antipsychotic, inpatientAbstract
Objective: To identify changes of prescription patterns in long term psychiatric inpatients in 1995 and 2009. Material and Methods: Cross sectional comparative study of two one-day-census, (06/15/1995 and 12/14/2009) at the Hospital Neuropsiquiátrico Alejandro Korn, Argentina. Records of prescribed psychotropic agents to all patients in long stay wards were examined. Results: The number of hospitalized patients decreased 33% from 1995 (n=1048) to 2009 (n=698), with increases in male gender (44% a 57%) and hospitalizations lasting more than 20 years (29% a 40%). Schizophrenia remained as the most prevalent diagnosis followed by learning disabilities/mental retardation (45% and 27% in 1995, respectively, 44% and 33% in 2009). The average antipsychotic dosis in schizophrenia was almost the same, the equivalent of around 760 mg of chlorpromazine. Patients on antipsychotic doses above an equivalent of 1200 mg decreased from 28% to 23,9%. Around 80% of those with learning disabilities were prescribed antipsychotics on both census. Antipsychotic polypharmacy increased 6,7% in schizophrenia (61%) and decreased 12,6% in learning disabilities (45%), and 6,5% in all inpatients (49%). Haloperidol and levomepromazine were still the more frequently prescribed antipsychotics while the use of anticholinergic agents diminished in a 21%. Regarding sedatives, the use of benzodiazepines and promethazine increased (15% and 19% respectively), while around 35% in both census was still receiving levomepromazine. Discussion: The introduction of atypical antipsychotic was not followed by great improvements in the rational use of psychotropics drugs, except for less antipsychotic polypharmacy in learning disabilities and of anticholinergics in the general population. Conclusion: The increase in antipsychotic polypharmacy in schizophrenia and the continuous use of benzodiazepines highlight the need to bring the usual practice closer to the evidence provided by clinical research.
Downloads
References
Centorrino F, Cincotta SL, Talamo A, Fogarty KV, Guzzetta F, Saadeh MG, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry. 2008; 49(1): 65-9. DOI: 10.1016/j.comppsych.2007.08.002
Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 2003;12(1):41-8. DOI: 10.1002/pds.783
Bitter I, Chou JC, Ungvari GS, Tang WK, Xiang Z, Iwanami A, et al. Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry. 2003;36(4):143-9. DOI: 10.1055/s-2003-41199
Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol. 2003;17(2):223-9. DOI: 10.1177/0269881103017002012
Gaviria AM, Franco JG, Aguado V, Rico G, Labad J, de Pablo J, et al. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona. PLoS One. 2015;10(10):e0139403. DOI: 10.1371/journal.pone.0139403
Broekema WJ, de Groot IW, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharm World Sci. 2007;29(3):126-30. DOI: 10.1007/s11096-006-9063-1
Bret P, Bonnet F, Bret MC, Jaffré A. Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone. Encephale. 2002;28(4):329-42.
Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry. 1999;14(1):33-40. DOI: 10.1016/s0924-9338(99)80713-5
Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527-42. DOI: 10.1517/14740338.2012.683523
Sadock B, Sadock V, Ruiz P. Kaplan & Sadock's comprehensive textbook of psychiatry. 9th ed. Philadelphia: Wolters Kluwer; 2009. p. 3326.
Zieher LM. Alvano SA. Psiconeurofarmacología clínica y sus bases neurocientíficas. 3a. Ed. Buenos Aires: Editorial Ursino; 2003. p.105.
National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Treatment and Management. London: National Institute for Health and Care Excellence; 2014. (Citado el 13 de Julio del 2021). Disponible en: www.nice.org.uk/CG178
Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry. 2017;62(9):604-16. DOI: 10.1177/0706743717720448
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-78. DOI: 10.3109/15622975.2012.696143
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2-44. DOI: 10.3109/15622975.2012.739708
Bojórquez Giraldo E, Arévalo Alván A, Castro Cisneros K, Ludowieg Casinelli L, Orihuela Fernández S. Patrones de prescripción de psicofármacos en pacientes con esquizofrenia y trastornos relacionados internados en el Hospital Víctor Larco Herrera, 2015. An la Fac Med. 2018;78(4):386. DOI: 10.15381/anales.v78i4.14258
Volpe FM, Santos AS, Rodrigues LS, Rocha RR, de Magalhães PG, Ruas CM. Current inpatient prescription practices for the treatment of schizophrenia in public hospitals of Minas Gerais, Brazil. Rev Bras Psiquiatr. 2017;39(2):190–2. DOI: 10.1590/1516-4446-2016-2047.
Costa J de O, Ceccato M das GB, Melo APS, Acurcio F de A, Guimarães MDC. Diferenças de gênero e polifarmácia psicotrópica em pacientes psiquiátricos no Brasil: Uma análise transversal do projeto PESSOAS. Cad Saude Publica. 2017;33(4):1–13. DOI: 10.1590/0102-311X00168915
Ayenew W, Asmamaw G, Bitew T. Antipsychotic Polypharmacy among patients with schizophrenia in Africa: A Systematic review and meta-analysis. Int J Neuropsychopharmacol. 2021;24(12):956-964. doi: 10.1093/ijnp/pyab046
Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122-7. DOI: 10.1192/bjp.188.2.122
Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700-6. DOI: 10.1176/appi.ajp.161.4.700
Szmulewicz AG, Angriman F, Pedroso FE, Vazquez C, Martino DJ. Long-Term Antipsychotic Use and Major Cardiovascular Events: A Retrospective Cohort Study. J Clin Psychiatry. 2017;78(8):e905-e912. DOI: 10.4088/JCP.16m10976
Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, Janssen M, Appelo D, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890-6. DOI: 10.1001/archinternmed.2008.3
Fujita J, Nishida A, Sakata M, Noda T, Ito H. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia. Psychiatry Clin Neurosci. 2013;67(5):345-51. DOI: 10.1111/pcn.12056
Ballon J, Stroup TS. Polypharmacy for schizophrenia. Curr Opin Psychiatry. 2013;26(2):208-13. DOI: 10.1097/YCO.0b013e32835d9efb .
Cermignani E, Escudero M, Rodriguez J, Buschiazzo H. Estudio descriptivo de uso de fármacos en un hospital neuropsiquiátrico. Medicamentos y Salud. 1998; 2(3):111-120. (Citado el 13 de Julio del 2021). Disponible en: https://www.yumpu.com/es/document/view/20787039/estudio-descriptivo-del-uso-de-farmacos-en-un-femeba-salud
de Menil V, Cohen A. Rational use and rationale for use: psychiatric medication at an Argentine institution for intellectual disability. Transcult Psychiatry. 2009;46(4):651-71. DOI: 10.1177/1363461509351377
Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res. 1974;11:65-9. DOI: 10.1016/0022-3956(74)90071-5
Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-7. DOI: 10.4088/jcp.v64n0607
Campbell M, Young PI, Bateman DN, Smith JM, Thomas SH. The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol. 1999;47(1):13-22. DOI: 10.1046/j.1365-2125.1999.00849.x
Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18-28. DOI: 10.1016/j.schres.2012.03.018
National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges NG11. London: NICE; 2015. (Citado el 13 de Julio del 2021). Disponible en: https://www.nice.org.uk/guidance/ng11
Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200(5):387-92. DOI: 10.1192/bjp.bp.111.101485
Tor PC, Ng TP, Yong KH, Sim K, Xiang YT, Wang CY, et al. Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008. Int J Neuropsychopharmacol. 2011;14(6):735-45. DOI: 10.1017/S146114571000163X
Citrome L. Long-acting injectable antipsychotics: what, when, and how. CNS Spectr. 2021 04;26(2):118-29. DOI: 10.1017/S1092852921000249
Karpov B, Joffe G, Aaltonen K, Oksanen J, Suominen K, Melartin T, et al. Self-reported treatment adherence among psychiatric in- and outpatients. Nord J Psychiatry. 2018;72(7):526-33. DOI: 10.1080/08039488.2018.1538387
Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702-8. DOI: 10.1176/appi.ajp.2011.10060908
Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019;76(5):499-507. DOI: 10.1001/jamapsychiatry.2018.4320
RNP is distributed under a 